Winson96的个人主页 - 老虎社区

Winson96

Winson96

暂无个人介绍

IP属地：未知

6关注

1粉丝

0主题

0勋章

2021-09-16

Hi

Cathie Wood Sells Another $61.7M Tesla Shares, Marking 4th Day Of Trimming Stake In Elon Musk Company This Month<blockquote>Cathie Wood又出售了价值6170万美元的特斯拉股票，这是本月第四天减持Elon Musk公司股份</blockquote>

2021-09-16

[Grin]

抱歉，原内容已删除

2021-09-15

[Strong] [Strong] [Strong]

Moderna stock jumped 4% in morning trading<blockquote>Moderna股价早盘上涨4%</blockquote>

2021-09-12

Up up up, to the sky😀

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4089439192591850","uuid":"4089439192591850","gmtCreate":1626336372374,"gmtModify":1631496746002,"name":"Winson96","pinyin":"winson96","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/ccaab866d210ccee630438cdf8ab4194","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":6,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":885181835,"gmtCreate":1631764947127,"gmtModify":1631890895188,"author":{"id":"4089439192591850","authorId":"4089439192591850","name":"Winson96","avatar":"https://static.tigerbbs.com/ccaab866d210ccee630438cdf8ab4194","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089439192591850","authorIdStr":"4089439192591850"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/885181835","repostId":"1118309831","repostType":4,"repost":{"id":"1118309831","kind":"news","pubTimestamp":1631761632,"share":"https://www.laohu8.com/m/news/1118309831?lang=zh_CN&edition=full","pubTime":"2021-09-16 11:07","market":"us","language":"en","title":"Cathie Wood Sells Another $61.7M Tesla Shares, Marking 4th Day Of Trimming Stake In Elon Musk Company This Month<blockquote>Cathie Wood又出售了价值6170万美元的特斯拉股票，这是本月第四天减持Elon Musk公司股份</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1118309831","media":"Benzinga","summary":"Cathie Wood-led Ark Invest on Wednesday further trimmed some of its stake in Tesla Inc, booking prof","content":"<p><div> Cathie Wood-led Ark Invest on Wednesday further trimmed some of its stake in Tesla Inc, booking profits as the stock continued to show signs of recovery after months of dull performance this year. The...</p><p><blockquote><div>凯西·伍德(Cathie Wood)领导的方舟投资(Ark Invest)周三进一步减持了特斯拉公司的部分股份，由于该股在今年数月的低迷表现后继续显示出复苏迹象，因此录得利润。这...</div></blockquote></p><p>  <a href=\"https://www.benzinga.com/news/21/09/22964062/cathie-wood-sells-another-61-7m-tesla-shares-marking-4th-day-of-trimming-stake-in-elon-musk-company\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://www.benzinga.com/news/21/09/22964062/cathie-wood-sells-another-61-7m-tesla-shares-marking-4th-day-of-trimming-stake-in-elon-musk-company\">网页连接</a></blockquote></p><p></p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Sells Another $61.7M Tesla Shares, Marking 4th Day Of Trimming Stake In Elon Musk Company This Month<blockquote>Cathie Wood又出售了价值6170万美元的特斯拉股票，这是本月第四天减持Elon Musk公司股份</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Sells Another $61.7M Tesla Shares, Marking 4th Day Of Trimming Stake In Elon Musk Company This Month<blockquote>Cathie Wood又出售了价值6170万美元的特斯拉股票，这是本月第四天减持Elon Musk公司股份</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Benzinga</strong><span class=\"h-time small\">2021-09-16 11:07</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> Cathie Wood-led Ark Invest on Wednesday further trimmed some of its stake in Tesla Inc, booking profits as the stock continued to show signs of recovery after months of dull performance this year. The...</p><p><blockquote><div>凯西·伍德(Cathie Wood)领导的方舟投资(Ark Invest)周三进一步减持了特斯拉公司的部分股份，由于该股在今年数月的低迷表现后继续显示出复苏迹象，因此录得利润。这...</div></blockquote></p><p>  <a href=\"https://www.benzinga.com/news/21/09/22964062/cathie-wood-sells-another-61-7m-tesla-shares-marking-4th-day-of-trimming-stake-in-elon-musk-company\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://www.benzinga.com/news/21/09/22964062/cathie-wood-sells-another-61-7m-tesla-shares-marking-4th-day-of-trimming-stake-in-elon-musk-company\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.benzinga.com/news/21/09/22964062/cathie-wood-sells-another-61-7m-tesla-shares-marking-4th-day-of-trimming-stake-in-elon-musk-company\">Benzinga</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.benzinga.com/news/21/09/22964062/cathie-wood-sells-another-61-7m-tesla-shares-marking-4th-day-of-trimming-stake-in-elon-musk-company","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118309831","content_text":"Cathie Wood-led Ark Invest on Wednesday further trimmed some of its stake in Tesla Inc, booking profits as the stock continued to show signs of recovery after months of dull performance this year.\nThe popular asset management firm sold 81,609 shares — estimated to be worth $61.7 million — in the Elon Musk-led company on Wednesday, its fourth such trade in Tesla in September.\nWith the latest sales, Ark Invest has trimmed a total of 354,181 shares — estimated to be worth about $267.7 million — in the Palo Alto, California-based company so far this month.\nTesla shares, which have risen about 6% since the beginning of this month, closed 1.52% higher at $755.83 a share on Wednesday. On a YTD basis, Tesla shares have risen about 3.57%.\nArk Invest deployed the Ark Next Generation Internet ETF\nARKW+undefined%and the Ark Innovation ETFARKK+undefined%to sell shares in Tesla. Ark Invest also owns shares in Tesla via the Ark Autonomous Technology & Robotics ETF(BATS:ARKQ).\nThe popular New York-based investment management firm has a large exposure in Tesla, a stock it predicts will hit the$3,000 mark at the end of 2025.  Ark Invest has bought most of Tesla shares at far lower levels and Wood has said the firm isn't hesitant in booking profits on portfolio companies when they run up too high and then buy back at lower prices once they retreat.\nTesla ranks as the top-most-holding in each of the three ETFs and Ark held a total of 4.21 million shares — worth $3.13 billion — in the electric vehicle company, ahead of Wednesday’s trades. No other Ark ETF owns shares in Tesla.\nHere are some of the other key trades for Ark on Wednesday:\nBought 92,058 shares in Robinhood Markets Inc\nSold 2,398 shares in Alphabet Inc\nBought 538,680 shares in UiPath Inc\nSold 62,840 shares in Iridium Communications Inc","news_type":1,"symbols_score_info":{"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":2622,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885183363,"gmtCreate":1631764806652,"gmtModify":1631890895198,"author":{"id":"4089439192591850","authorId":"4089439192591850","name":"Winson96","avatar":"https://static.tigerbbs.com/ccaab866d210ccee630438cdf8ab4194","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089439192591850","authorIdStr":"4089439192591850"},"themes":[],"htmlText":"[Grin]&nbsp;","listText":"[Grin]&nbsp;","text":"[Grin]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/885183363","repostId":"2167592712","repostType":4,"isVote":1,"tweetType":1,"viewCount":1434,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":882211215,"gmtCreate":1631694787837,"gmtModify":1631890895215,"author":{"id":"4089439192591850","authorId":"4089439192591850","name":"Winson96","avatar":"https://static.tigerbbs.com/ccaab866d210ccee630438cdf8ab4194","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089439192591850","authorIdStr":"4089439192591850"},"themes":[],"htmlText":"[Strong]&nbsp;[Strong]&nbsp;[Strong]&nbsp;","listText":"[Strong]&nbsp;[Strong]&nbsp;[Strong]&nbsp;","text":"[Strong] [Strong] [Strong]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/882211215","repostId":"1118676828","repostType":4,"repost":{"id":"1118676828","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1631631830,"share":"https://www.laohu8.com/m/news/1118676828?lang=zh_CN&edition=full","pubTime":"2021-09-14 23:03","market":"us","language":"en","title":"Moderna stock jumped 4% in morning trading<blockquote>Moderna股价早盘上涨4%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1118676828","media":"Tiger Newspress","summary":"Moderna stock jumped 4% in morning trading as a recent study found that the Moderna COVID-19 vaccine","content":"<p>Moderna stock jumped 4% in morning trading&nbsp;as&nbsp;a recent study found that the Moderna COVID-19 vaccine produces higher antibody levels than the Pfizer-BioNTech vaccine.</p><p><blockquote>Moderna股价在早盘交易中上涨4%，因为最近的一项研究发现，Moderna COVID-19疫苗产生的抗体水平高于辉瑞-BioNTech疫苗。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/289c5ec428971234976d932651a5f86d\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <ul>  <li>A recent study found that the Moderna COVID-19 vaccine produces higher antibody levels than the Pfizer-BioNTech vaccine.</li>  <li>This is possibly due to its higher mRNA content and a longer waiting period between doses.</li>  <li>Antibody tests are not entirely predictive of the body’s immunity against COVID-19.</li> </ul> A recent study found that the Moderna COVID-19 vaccine produced twice as many antibodies in recipients as the Pfizer-BioNTech vaccine.</p><p><blockquote><ul><li>最近的一项研究发现，Moderna新冠肺炎疫苗比辉瑞-BioNTech疫苗产生更高的抗体水平。</li><li>这可能是由于其较高的mRNA含量和较长的剂量之间的等待期。</li><li>抗体测试并不能完全预测人体对新冠肺炎的免疫力。</li></ul>最近的一项研究发现，Moderna新冠肺炎疫苗在接受者体内产生的抗体是辉瑞-BioNTech疫苗的两倍。</blockquote></p><p> The August study, published in&nbsp;<i>JAMA</i>, compared the antibody levels of 1647 healthcare workers before and six to 10 weeks after vaccination. The researchers observed significantly higher antibody levels among the recipients of the Moderna vaccine compared to the recipients of the Pfizer-BioNTech vaccine.</p><p><blockquote>八月份的研究发表在<i>贾马</i>，比较了1647名医护人员在接种疫苗前和接种后6至10周的抗体水平。研究人员观察到，与辉瑞-BioNTech疫苗的接受者相比，Moderna疫苗的接受者的抗体水平明显更高。</blockquote></p><p> Among all the participants who had a previous COVID-19 infection, those who were vaccinated with the Moderna vaccine still carried more antibodies.</p><p><blockquote>在所有先前感染过新冠病毒的参与者中，接种了Moderna疫苗的人仍然携带了更多的抗体。</blockquote></p><p> However, more research is needed to understand whether the difference in antibody levels leads to different levels of protection against the virus. Experts stress that testing for antibodies isn't the only way of measuring protection.</p><p><blockquote>然而，需要更多的研究来了解抗体水平的差异是否会导致对病毒的不同保护水平。专家强调，抗体检测并不是衡量保护的唯一方法。</blockquote></p><p> <b>Why Does Moderna Produce Higher Antibody Levels?</b></p><p><blockquote><b>为什么Moderna会产生更高的抗体水平？</b></blockquote></p><p> According to the authors of the study, the Moderna COVID-19 vaccine contains more mRNA and requires a longer waiting period than Pfizer-BioNTech, which may have played a role.</p><p><blockquote>根据该研究的作者，与辉瑞-BioNTech相比，Moderna新冠肺炎疫苗含有更多的mRNA，需要更长的等待时间，这可能起到了一定的作用。</blockquote></p><p> “It is also possible that the mRNA itself used in the Moderna vaccine may have led to this difference independent of the dose in the vaccine or the timing of the two shots,\"Richard Martinello, MD, Yale Medicine infectious diseases specialist and associate professor of medicine and pediatrics at the Yale School of Medicine, who was not involved in the study, tells Verywell.</p><p><blockquote>“也有可能是Moderna疫苗中使用的mRNA本身导致了这种差异，与疫苗的剂量或两次注射的时间无关，”耶鲁大学医学传染病专家兼副教授Richard Martinello医学博士告诉Verywell，他没有参与这项研究。</blockquote></p><p> The Moderna vaccine contains more mRNA within the vaccine compared to the Pfizer dosage. And doses are given 28 days apart, compared to 21 days for the Pfizer vaccine.</p><p><blockquote>与辉瑞剂量相比，Moderna疫苗在疫苗中含有更多的mRNA。接种间隔28天，而辉瑞疫苗为21天。</blockquote></p><p> Still, further research is needed to understand why Moderna produced more antibodies. Experts still aren't sure if varying antibody levels translate to a difference in protection against COVID-19.</p><p><blockquote>尽管如此，还需要进一步的研究来了解为什么Moderna会产生更多的抗体。专家们仍然不确定不同的抗体水平是否会转化为对COVID-19保护的差异。</blockquote></p><p> <b>Antibody Tests Don’t Tell the Whole Story</b></p><p><blockquote><b>抗体测试并不能说明全部情况</b></blockquote></p><p> The study has notable limitations since it focused solely on healthcare workers and did not include data on cellular immunity.</p><p><blockquote>这项研究有明显的局限性，因为它只关注医护人员，不包括细胞免疫的数据。</blockquote></p><p> “Antibody levels have been found to provide a good measure of one’s protection against infection,” Martinello says. “However, it is known that cellular immunity plays a key role in the protection against and response to COVID. This is much more difficult to measure so it is not a routine test available from clinical laboratories. Therefore, while it is possible that the Moderna vaccine may be found to be more protective than the Pfizer vaccine, that remains to be seen.”</p><p><blockquote>“已经发现抗体水平可以很好地衡量一个人对感染的保护，”马蒂内洛说。“然而，众所周知，细胞免疫在预防和应对COVID方面发挥着关键作用。这更难测量，因此它不是临床实验室可用的常规测试。因此，虽然Moderna疫苗可能会被发现比辉瑞疫苗更具保护性，但这还有待观察。”</blockquote></p><p> A May study found that antibody levels can be predictive of protection from COVID-19 infection, but the researchers acknowledged that it's important to study T cell and B cell memory responses as well.</p><p><blockquote>5月份的一项研究发现，抗体水平可以预测对COVID-19感染的保护，但研究人员承认，研究T细胞和B细胞记忆反应也很重要。</blockquote></p><p> Although antibody levels are much simpler and cheaper to measure, and higher levels are likely to be more protective, they’re not a good measure of the degree and/or duration of protection an individual has against COVID-19,Stanley H. Weiss, MD, professor of medicine at the Rutgers New Jersey Medical School and professor of biostatistics at the Rutgers School of Public Health, tells Verywell.</p><p><blockquote>罗格斯大学新泽西医学院医学教授和罗格斯大学公共卫生学院生物统计学教授Stanley H.Weiss医学博士告诉Verywell，尽管抗体水平的测量更简单、更便宜，而且更高的水平可能更具保护性，但它们并不能很好地衡量个人对新冠肺炎的保护程度和/或持续时间。</blockquote></p><p> Earlier this year, the Food and Drug Administration (FDA) issued guidance saying that antibody tests should not be used to assess COVID-19 immunity after vaccination.3Researchers say that antibody tests are valuable public health tools that have very little use for individuals, and should not influence personal decision-making.</p><p><blockquote>今年早些时候，美国食品药品监督管理局（FDA）发布指南称，抗体测试不应用于评估接种疫苗后的新冠肺炎免疫力。3研究人员表示，抗体测试是有价值的公共卫生工具，对个人用处不大，不应影响个人决策。</blockquote></p><p> “There is ample data showing that some persons without any detectable antibodies have good protection due to cellular immunity,” Weiss says. “There is also ample data of breakthrough infection among persons who have anti-Covid antibodies.”</p><p><blockquote>“有大量数据表明，一些没有任何可检测抗体的人由于细胞免疫而具有良好的保护作用，”韦斯说。“也有大量数据表明具有抗新冠抗体的人出现突破性感染。”</blockquote></p><p> A March study found that cellular immunity remains robust six months after natural infection even though antibodies against the virus may fall below detectable levels. The findings show promise that COVID-19 vaccines elicit a similar response in the body.</p><p><blockquote>三月份的一项研究发现，尽管针对病毒的抗体可能低于可检测水平，但自然感染后六个月细胞免疫力仍然很强。这些发现表明，新冠肺炎疫苗有望在体内引发类似的反应。</blockquote></p><p> “In an individual person for clinical purposes, and especially outside of a carefully designed research study, I recommend against antibody testing,” Weiss says. “Neither a positive nor negative result gives you definitive information. My recommendation is for a decision to be based on general clinical criteria, not on an antibody test.”</p><p><blockquote>“出于临床目的，尤其是在精心设计的研究之外，我建议不要对个人进行抗体测试，”韦斯说。“阳性或阴性结果都不能给你明确的信息。我的建议是根据一般临床标准做出决定，而不是根据抗体测试。”</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna stock jumped 4% in morning trading<blockquote>Moderna股价早盘上涨4%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna stock jumped 4% in morning trading<blockquote>Moderna股价早盘上涨4%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-09-14 23:03</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Moderna stock jumped 4% in morning trading&nbsp;as&nbsp;a recent study found that the Moderna COVID-19 vaccine produces higher antibody levels than the Pfizer-BioNTech vaccine.</p><p><blockquote>Moderna股价在早盘交易中上涨4%，因为最近的一项研究发现，Moderna COVID-19疫苗产生的抗体水平高于辉瑞-BioNTech疫苗。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/289c5ec428971234976d932651a5f86d\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <ul>  <li>A recent study found that the Moderna COVID-19 vaccine produces higher antibody levels than the Pfizer-BioNTech vaccine.</li>  <li>This is possibly due to its higher mRNA content and a longer waiting period between doses.</li>  <li>Antibody tests are not entirely predictive of the body’s immunity against COVID-19.</li> </ul> A recent study found that the Moderna COVID-19 vaccine produced twice as many antibodies in recipients as the Pfizer-BioNTech vaccine.</p><p><blockquote><ul><li>最近的一项研究发现，Moderna新冠肺炎疫苗比辉瑞-BioNTech疫苗产生更高的抗体水平。</li><li>这可能是由于其较高的mRNA含量和较长的剂量之间的等待期。</li><li>抗体测试并不能完全预测人体对新冠肺炎的免疫力。</li></ul>最近的一项研究发现，Moderna新冠肺炎疫苗在接受者体内产生的抗体是辉瑞-BioNTech疫苗的两倍。</blockquote></p><p> The August study, published in&nbsp;<i>JAMA</i>, compared the antibody levels of 1647 healthcare workers before and six to 10 weeks after vaccination. The researchers observed significantly higher antibody levels among the recipients of the Moderna vaccine compared to the recipients of the Pfizer-BioNTech vaccine.</p><p><blockquote>八月份的研究发表在<i>贾马</i>，比较了1647名医护人员在接种疫苗前和接种后6至10周的抗体水平。研究人员观察到，与辉瑞-BioNTech疫苗的接受者相比，Moderna疫苗的接受者的抗体水平明显更高。</blockquote></p><p> Among all the participants who had a previous COVID-19 infection, those who were vaccinated with the Moderna vaccine still carried more antibodies.</p><p><blockquote>在所有先前感染过新冠病毒的参与者中，接种了Moderna疫苗的人仍然携带了更多的抗体。</blockquote></p><p> However, more research is needed to understand whether the difference in antibody levels leads to different levels of protection against the virus. Experts stress that testing for antibodies isn't the only way of measuring protection.</p><p><blockquote>然而，需要更多的研究来了解抗体水平的差异是否会导致对病毒的不同保护水平。专家强调，抗体检测并不是衡量保护的唯一方法。</blockquote></p><p> <b>Why Does Moderna Produce Higher Antibody Levels?</b></p><p><blockquote><b>为什么Moderna会产生更高的抗体水平？</b></blockquote></p><p> According to the authors of the study, the Moderna COVID-19 vaccine contains more mRNA and requires a longer waiting period than Pfizer-BioNTech, which may have played a role.</p><p><blockquote>根据该研究的作者，与辉瑞-BioNTech相比，Moderna新冠肺炎疫苗含有更多的mRNA，需要更长的等待时间，这可能起到了一定的作用。</blockquote></p><p> “It is also possible that the mRNA itself used in the Moderna vaccine may have led to this difference independent of the dose in the vaccine or the timing of the two shots,\"Richard Martinello, MD, Yale Medicine infectious diseases specialist and associate professor of medicine and pediatrics at the Yale School of Medicine, who was not involved in the study, tells Verywell.</p><p><blockquote>“也有可能是Moderna疫苗中使用的mRNA本身导致了这种差异，与疫苗的剂量或两次注射的时间无关，”耶鲁大学医学传染病专家兼副教授Richard Martinello医学博士告诉Verywell，他没有参与这项研究。</blockquote></p><p> The Moderna vaccine contains more mRNA within the vaccine compared to the Pfizer dosage. And doses are given 28 days apart, compared to 21 days for the Pfizer vaccine.</p><p><blockquote>与辉瑞剂量相比，Moderna疫苗在疫苗中含有更多的mRNA。接种间隔28天，而辉瑞疫苗为21天。</blockquote></p><p> Still, further research is needed to understand why Moderna produced more antibodies. Experts still aren't sure if varying antibody levels translate to a difference in protection against COVID-19.</p><p><blockquote>尽管如此，还需要进一步的研究来了解为什么Moderna会产生更多的抗体。专家们仍然不确定不同的抗体水平是否会转化为对COVID-19保护的差异。</blockquote></p><p> <b>Antibody Tests Don’t Tell the Whole Story</b></p><p><blockquote><b>抗体测试并不能说明全部情况</b></blockquote></p><p> The study has notable limitations since it focused solely on healthcare workers and did not include data on cellular immunity.</p><p><blockquote>这项研究有明显的局限性，因为它只关注医护人员，不包括细胞免疫的数据。</blockquote></p><p> “Antibody levels have been found to provide a good measure of one’s protection against infection,” Martinello says. “However, it is known that cellular immunity plays a key role in the protection against and response to COVID. This is much more difficult to measure so it is not a routine test available from clinical laboratories. Therefore, while it is possible that the Moderna vaccine may be found to be more protective than the Pfizer vaccine, that remains to be seen.”</p><p><blockquote>“已经发现抗体水平可以很好地衡量一个人对感染的保护，”马蒂内洛说。“然而，众所周知，细胞免疫在预防和应对COVID方面发挥着关键作用。这更难测量，因此它不是临床实验室可用的常规测试。因此，虽然Moderna疫苗可能会被发现比辉瑞疫苗更具保护性，但这还有待观察。”</blockquote></p><p> A May study found that antibody levels can be predictive of protection from COVID-19 infection, but the researchers acknowledged that it's important to study T cell and B cell memory responses as well.</p><p><blockquote>5月份的一项研究发现，抗体水平可以预测对COVID-19感染的保护，但研究人员承认，研究T细胞和B细胞记忆反应也很重要。</blockquote></p><p> Although antibody levels are much simpler and cheaper to measure, and higher levels are likely to be more protective, they’re not a good measure of the degree and/or duration of protection an individual has against COVID-19,Stanley H. Weiss, MD, professor of medicine at the Rutgers New Jersey Medical School and professor of biostatistics at the Rutgers School of Public Health, tells Verywell.</p><p><blockquote>罗格斯大学新泽西医学院医学教授和罗格斯大学公共卫生学院生物统计学教授Stanley H.Weiss医学博士告诉Verywell，尽管抗体水平的测量更简单、更便宜，而且更高的水平可能更具保护性，但它们并不能很好地衡量个人对新冠肺炎的保护程度和/或持续时间。</blockquote></p><p> Earlier this year, the Food and Drug Administration (FDA) issued guidance saying that antibody tests should not be used to assess COVID-19 immunity after vaccination.3Researchers say that antibody tests are valuable public health tools that have very little use for individuals, and should not influence personal decision-making.</p><p><blockquote>今年早些时候，美国食品药品监督管理局（FDA）发布指南称，抗体测试不应用于评估接种疫苗后的新冠肺炎免疫力。3研究人员表示，抗体测试是有价值的公共卫生工具，对个人用处不大，不应影响个人决策。</blockquote></p><p> “There is ample data showing that some persons without any detectable antibodies have good protection due to cellular immunity,” Weiss says. “There is also ample data of breakthrough infection among persons who have anti-Covid antibodies.”</p><p><blockquote>“有大量数据表明，一些没有任何可检测抗体的人由于细胞免疫而具有良好的保护作用，”韦斯说。“也有大量数据表明具有抗新冠抗体的人出现突破性感染。”</blockquote></p><p> A March study found that cellular immunity remains robust six months after natural infection even though antibodies against the virus may fall below detectable levels. The findings show promise that COVID-19 vaccines elicit a similar response in the body.</p><p><blockquote>三月份的一项研究发现，尽管针对病毒的抗体可能低于可检测水平，但自然感染后六个月细胞免疫力仍然很强。这些发现表明，新冠肺炎疫苗有望在体内引发类似的反应。</blockquote></p><p> “In an individual person for clinical purposes, and especially outside of a carefully designed research study, I recommend against antibody testing,” Weiss says. “Neither a positive nor negative result gives you definitive information. My recommendation is for a decision to be based on general clinical criteria, not on an antibody test.”</p><p><blockquote>“出于临床目的，尤其是在精心设计的研究之外，我建议不要对个人进行抗体测试，”韦斯说。“阳性或阴性结果都不能给你明确的信息。我的建议是根据一般临床标准做出决定，而不是根据抗体测试。”</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118676828","content_text":"Moderna stock jumped 4% in morning trading as a recent study found that the Moderna COVID-19 vaccine produces higher antibody levels than the Pfizer-BioNTech vaccine.\n\n\nA recent study found that the Moderna COVID-19 vaccine produces higher antibody levels than the Pfizer-BioNTech vaccine.\nThis is possibly due to its higher mRNA content and a longer waiting period between doses.\nAntibody tests are not entirely predictive of the body’s immunity against COVID-19.\n\nA recent study found that the Moderna COVID-19 vaccine produced twice as many antibodies in recipients as the Pfizer-BioNTech vaccine.\nThe August study, published in JAMA, compared the antibody levels of 1647 healthcare workers before and six to 10 weeks after vaccination. The researchers observed significantly higher antibody levels among the recipients of the Moderna vaccine compared to the recipients of the Pfizer-BioNTech vaccine.\nAmong all the participants who had a previous COVID-19 infection, those who were vaccinated with the Moderna vaccine still carried more antibodies.\nHowever, more research is needed to understand whether the difference in antibody levels leads to different levels of protection against the virus. Experts stress that testing for antibodies isn't the only way of measuring protection.\nWhy Does Moderna Produce Higher Antibody Levels?\nAccording to the authors of the study, the Moderna COVID-19 vaccine contains more mRNA and requires a longer waiting period than Pfizer-BioNTech, which may have played a role.\n“It is also possible that the mRNA itself used in the Moderna vaccine may have led to this difference independent of the dose in the vaccine or the timing of the two shots,\"Richard Martinello, MD, Yale Medicine infectious diseases specialist and associate professor of medicine and pediatrics at the Yale School of Medicine, who was not involved in the study, tells Verywell.\nThe Moderna vaccine contains more mRNA within the vaccine compared to the Pfizer dosage. And doses are given 28 days apart, compared to 21 days for the Pfizer vaccine.\nStill, further research is needed to understand why Moderna produced more antibodies. Experts still aren't sure if varying antibody levels translate to a difference in protection against COVID-19.\nAntibody Tests Don’t Tell the Whole Story\nThe study has notable limitations since it focused solely on healthcare workers and did not include data on cellular immunity.\n“Antibody levels have been found to provide a good measure of one’s protection against infection,” Martinello says. “However, it is known that cellular immunity plays a key role in the protection against and response to COVID. This is much more difficult to measure so it is not a routine test available from clinical laboratories. Therefore, while it is possible that the Moderna vaccine may be found to be more protective than the Pfizer vaccine, that remains to be seen.”\nA May study found that antibody levels can be predictive of protection from COVID-19 infection, but the researchers acknowledged that it's important to study T cell and B cell memory responses as well.\nAlthough antibody levels are much simpler and cheaper to measure, and higher levels are likely to be more protective, they’re not a good measure of the degree and/or duration of protection an individual has against COVID-19,Stanley H. Weiss, MD, professor of medicine at the Rutgers New Jersey Medical School and professor of biostatistics at the Rutgers School of Public Health, tells Verywell.\nEarlier this year, the Food and Drug Administration (FDA) issued guidance saying that antibody tests should not be used to assess COVID-19 immunity after vaccination.3Researchers say that antibody tests are valuable public health tools that have very little use for individuals, and should not influence personal decision-making.\n“There is ample data showing that some persons without any detectable antibodies have good protection due to cellular immunity,” Weiss says. “There is also ample data of breakthrough infection among persons who have anti-Covid antibodies.”\nA March study found that cellular immunity remains robust six months after natural infection even though antibodies against the virus may fall below detectable levels. The findings show promise that COVID-19 vaccines elicit a similar response in the body.\n“In an individual person for clinical purposes, and especially outside of a carefully designed research study, I recommend against antibody testing,” Weiss says. “Neither a positive nor negative result gives you definitive information. My recommendation is for a decision to be based on general clinical criteria, not on an antibody test.”","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1715,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":888158977,"gmtCreate":1631461211999,"gmtModify":1631890895224,"author":{"id":"4089439192591850","authorId":"4089439192591850","name":"Winson96","avatar":"https://static.tigerbbs.com/ccaab866d210ccee630438cdf8ab4194","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089439192591850","authorIdStr":"4089439192591850"},"themes":[],"htmlText":"Up up up, to the sky😀","listText":"Up up up, to the sky😀","text":"Up up up, to the sky😀","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/888158977","isVote":1,"tweetType":1,"viewCount":1591,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":882211215,"gmtCreate":1631694787837,"gmtModify":1631890895215,"author":{"id":"4089439192591850","authorId":"4089439192591850","name":"Winson96","avatar":"https://static.tigerbbs.com/ccaab866d210ccee630438cdf8ab4194","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089439192591850","idStr":"4089439192591850"},"themes":[],"htmlText":"[Strong]&nbsp;[Strong]&nbsp;[Strong]&nbsp;","listText":"[Strong]&nbsp;[Strong]&nbsp;[Strong]&nbsp;","text":"[Strong] [Strong] [Strong]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/882211215","repostId":"1118676828","repostType":4,"repost":{"id":"1118676828","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1631631830,"share":"https://www.laohu8.com/m/news/1118676828?lang=zh_CN&edition=full","pubTime":"2021-09-14 23:03","market":"us","language":"en","title":"Moderna stock jumped 4% in morning trading<blockquote>Moderna股价早盘上涨4%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1118676828","media":"Tiger Newspress","summary":"Moderna stock jumped 4% in morning trading as a recent study found that the Moderna COVID-19 vaccine","content":"<p>Moderna stock jumped 4% in morning trading&nbsp;as&nbsp;a recent study found that the Moderna COVID-19 vaccine produces higher antibody levels than the Pfizer-BioNTech vaccine.</p><p><blockquote>Moderna股价在早盘交易中上涨4%，因为最近的一项研究发现，Moderna COVID-19疫苗产生的抗体水平高于辉瑞-BioNTech疫苗。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/289c5ec428971234976d932651a5f86d\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <ul>  <li>A recent study found that the Moderna COVID-19 vaccine produces higher antibody levels than the Pfizer-BioNTech vaccine.</li>  <li>This is possibly due to its higher mRNA content and a longer waiting period between doses.</li>  <li>Antibody tests are not entirely predictive of the body’s immunity against COVID-19.</li> </ul> A recent study found that the Moderna COVID-19 vaccine produced twice as many antibodies in recipients as the Pfizer-BioNTech vaccine.</p><p><blockquote><ul><li>最近的一项研究发现，Moderna新冠肺炎疫苗比辉瑞-BioNTech疫苗产生更高的抗体水平。</li><li>这可能是由于其较高的mRNA含量和较长的剂量之间的等待期。</li><li>抗体测试并不能完全预测人体对新冠肺炎的免疫力。</li></ul>最近的一项研究发现，Moderna新冠肺炎疫苗在接受者体内产生的抗体是辉瑞-BioNTech疫苗的两倍。</blockquote></p><p> The August study, published in&nbsp;<i>JAMA</i>, compared the antibody levels of 1647 healthcare workers before and six to 10 weeks after vaccination. The researchers observed significantly higher antibody levels among the recipients of the Moderna vaccine compared to the recipients of the Pfizer-BioNTech vaccine.</p><p><blockquote>八月份的研究发表在<i>贾马</i>，比较了1647名医护人员在接种疫苗前和接种后6至10周的抗体水平。研究人员观察到，与辉瑞-BioNTech疫苗的接受者相比，Moderna疫苗的接受者的抗体水平明显更高。</blockquote></p><p> Among all the participants who had a previous COVID-19 infection, those who were vaccinated with the Moderna vaccine still carried more antibodies.</p><p><blockquote>在所有先前感染过新冠病毒的参与者中，接种了Moderna疫苗的人仍然携带了更多的抗体。</blockquote></p><p> However, more research is needed to understand whether the difference in antibody levels leads to different levels of protection against the virus. Experts stress that testing for antibodies isn't the only way of measuring protection.</p><p><blockquote>然而，需要更多的研究来了解抗体水平的差异是否会导致对病毒的不同保护水平。专家强调，抗体检测并不是衡量保护的唯一方法。</blockquote></p><p> <b>Why Does Moderna Produce Higher Antibody Levels?</b></p><p><blockquote><b>为什么Moderna会产生更高的抗体水平？</b></blockquote></p><p> According to the authors of the study, the Moderna COVID-19 vaccine contains more mRNA and requires a longer waiting period than Pfizer-BioNTech, which may have played a role.</p><p><blockquote>根据该研究的作者，与辉瑞-BioNTech相比，Moderna新冠肺炎疫苗含有更多的mRNA，需要更长的等待时间，这可能起到了一定的作用。</blockquote></p><p> “It is also possible that the mRNA itself used in the Moderna vaccine may have led to this difference independent of the dose in the vaccine or the timing of the two shots,\"Richard Martinello, MD, Yale Medicine infectious diseases specialist and associate professor of medicine and pediatrics at the Yale School of Medicine, who was not involved in the study, tells Verywell.</p><p><blockquote>“也有可能是Moderna疫苗中使用的mRNA本身导致了这种差异，与疫苗的剂量或两次注射的时间无关，”耶鲁大学医学传染病专家兼副教授Richard Martinello医学博士告诉Verywell，他没有参与这项研究。</blockquote></p><p> The Moderna vaccine contains more mRNA within the vaccine compared to the Pfizer dosage. And doses are given 28 days apart, compared to 21 days for the Pfizer vaccine.</p><p><blockquote>与辉瑞剂量相比，Moderna疫苗在疫苗中含有更多的mRNA。接种间隔28天，而辉瑞疫苗为21天。</blockquote></p><p> Still, further research is needed to understand why Moderna produced more antibodies. Experts still aren't sure if varying antibody levels translate to a difference in protection against COVID-19.</p><p><blockquote>尽管如此，还需要进一步的研究来了解为什么Moderna会产生更多的抗体。专家们仍然不确定不同的抗体水平是否会转化为对COVID-19保护的差异。</blockquote></p><p> <b>Antibody Tests Don’t Tell the Whole Story</b></p><p><blockquote><b>抗体测试并不能说明全部情况</b></blockquote></p><p> The study has notable limitations since it focused solely on healthcare workers and did not include data on cellular immunity.</p><p><blockquote>这项研究有明显的局限性，因为它只关注医护人员，不包括细胞免疫的数据。</blockquote></p><p> “Antibody levels have been found to provide a good measure of one’s protection against infection,” Martinello says. “However, it is known that cellular immunity plays a key role in the protection against and response to COVID. This is much more difficult to measure so it is not a routine test available from clinical laboratories. Therefore, while it is possible that the Moderna vaccine may be found to be more protective than the Pfizer vaccine, that remains to be seen.”</p><p><blockquote>“已经发现抗体水平可以很好地衡量一个人对感染的保护，”马蒂内洛说。“然而，众所周知，细胞免疫在预防和应对COVID方面发挥着关键作用。这更难测量，因此它不是临床实验室可用的常规测试。因此，虽然Moderna疫苗可能会被发现比辉瑞疫苗更具保护性，但这还有待观察。”</blockquote></p><p> A May study found that antibody levels can be predictive of protection from COVID-19 infection, but the researchers acknowledged that it's important to study T cell and B cell memory responses as well.</p><p><blockquote>5月份的一项研究发现，抗体水平可以预测对COVID-19感染的保护，但研究人员承认，研究T细胞和B细胞记忆反应也很重要。</blockquote></p><p> Although antibody levels are much simpler and cheaper to measure, and higher levels are likely to be more protective, they’re not a good measure of the degree and/or duration of protection an individual has against COVID-19,Stanley H. Weiss, MD, professor of medicine at the Rutgers New Jersey Medical School and professor of biostatistics at the Rutgers School of Public Health, tells Verywell.</p><p><blockquote>罗格斯大学新泽西医学院医学教授和罗格斯大学公共卫生学院生物统计学教授Stanley H.Weiss医学博士告诉Verywell，尽管抗体水平的测量更简单、更便宜，而且更高的水平可能更具保护性，但它们并不能很好地衡量个人对新冠肺炎的保护程度和/或持续时间。</blockquote></p><p> Earlier this year, the Food and Drug Administration (FDA) issued guidance saying that antibody tests should not be used to assess COVID-19 immunity after vaccination.3Researchers say that antibody tests are valuable public health tools that have very little use for individuals, and should not influence personal decision-making.</p><p><blockquote>今年早些时候，美国食品药品监督管理局（FDA）发布指南称，抗体测试不应用于评估接种疫苗后的新冠肺炎免疫力。3研究人员表示，抗体测试是有价值的公共卫生工具，对个人用处不大，不应影响个人决策。</blockquote></p><p> “There is ample data showing that some persons without any detectable antibodies have good protection due to cellular immunity,” Weiss says. “There is also ample data of breakthrough infection among persons who have anti-Covid antibodies.”</p><p><blockquote>“有大量数据表明，一些没有任何可检测抗体的人由于细胞免疫而具有良好的保护作用，”韦斯说。“也有大量数据表明具有抗新冠抗体的人出现突破性感染。”</blockquote></p><p> A March study found that cellular immunity remains robust six months after natural infection even though antibodies against the virus may fall below detectable levels. The findings show promise that COVID-19 vaccines elicit a similar response in the body.</p><p><blockquote>三月份的一项研究发现，尽管针对病毒的抗体可能低于可检测水平，但自然感染后六个月细胞免疫力仍然很强。这些发现表明，新冠肺炎疫苗有望在体内引发类似的反应。</blockquote></p><p> “In an individual person for clinical purposes, and especially outside of a carefully designed research study, I recommend against antibody testing,” Weiss says. “Neither a positive nor negative result gives you definitive information. My recommendation is for a decision to be based on general clinical criteria, not on an antibody test.”</p><p><blockquote>“出于临床目的，尤其是在精心设计的研究之外，我建议不要对个人进行抗体测试，”韦斯说。“阳性或阴性结果都不能给你明确的信息。我的建议是根据一般临床标准做出决定，而不是根据抗体测试。”</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna stock jumped 4% in morning trading<blockquote>Moderna股价早盘上涨4%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna stock jumped 4% in morning trading<blockquote>Moderna股价早盘上涨4%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-09-14 23:03</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Moderna stock jumped 4% in morning trading&nbsp;as&nbsp;a recent study found that the Moderna COVID-19 vaccine produces higher antibody levels than the Pfizer-BioNTech vaccine.</p><p><blockquote>Moderna股价在早盘交易中上涨4%，因为最近的一项研究发现，Moderna COVID-19疫苗产生的抗体水平高于辉瑞-BioNTech疫苗。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/289c5ec428971234976d932651a5f86d\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <ul>  <li>A recent study found that the Moderna COVID-19 vaccine produces higher antibody levels than the Pfizer-BioNTech vaccine.</li>  <li>This is possibly due to its higher mRNA content and a longer waiting period between doses.</li>  <li>Antibody tests are not entirely predictive of the body’s immunity against COVID-19.</li> </ul> A recent study found that the Moderna COVID-19 vaccine produced twice as many antibodies in recipients as the Pfizer-BioNTech vaccine.</p><p><blockquote><ul><li>最近的一项研究发现，Moderna新冠肺炎疫苗比辉瑞-BioNTech疫苗产生更高的抗体水平。</li><li>这可能是由于其较高的mRNA含量和较长的剂量之间的等待期。</li><li>抗体测试并不能完全预测人体对新冠肺炎的免疫力。</li></ul>最近的一项研究发现，Moderna新冠肺炎疫苗在接受者体内产生的抗体是辉瑞-BioNTech疫苗的两倍。</blockquote></p><p> The August study, published in&nbsp;<i>JAMA</i>, compared the antibody levels of 1647 healthcare workers before and six to 10 weeks after vaccination. The researchers observed significantly higher antibody levels among the recipients of the Moderna vaccine compared to the recipients of the Pfizer-BioNTech vaccine.</p><p><blockquote>八月份的研究发表在<i>贾马</i>，比较了1647名医护人员在接种疫苗前和接种后6至10周的抗体水平。研究人员观察到，与辉瑞-BioNTech疫苗的接受者相比，Moderna疫苗的接受者的抗体水平明显更高。</blockquote></p><p> Among all the participants who had a previous COVID-19 infection, those who were vaccinated with the Moderna vaccine still carried more antibodies.</p><p><blockquote>在所有先前感染过新冠病毒的参与者中，接种了Moderna疫苗的人仍然携带了更多的抗体。</blockquote></p><p> However, more research is needed to understand whether the difference in antibody levels leads to different levels of protection against the virus. Experts stress that testing for antibodies isn't the only way of measuring protection.</p><p><blockquote>然而，需要更多的研究来了解抗体水平的差异是否会导致对病毒的不同保护水平。专家强调，抗体检测并不是衡量保护的唯一方法。</blockquote></p><p> <b>Why Does Moderna Produce Higher Antibody Levels?</b></p><p><blockquote><b>为什么Moderna会产生更高的抗体水平？</b></blockquote></p><p> According to the authors of the study, the Moderna COVID-19 vaccine contains more mRNA and requires a longer waiting period than Pfizer-BioNTech, which may have played a role.</p><p><blockquote>根据该研究的作者，与辉瑞-BioNTech相比，Moderna新冠肺炎疫苗含有更多的mRNA，需要更长的等待时间，这可能起到了一定的作用。</blockquote></p><p> “It is also possible that the mRNA itself used in the Moderna vaccine may have led to this difference independent of the dose in the vaccine or the timing of the two shots,\"Richard Martinello, MD, Yale Medicine infectious diseases specialist and associate professor of medicine and pediatrics at the Yale School of Medicine, who was not involved in the study, tells Verywell.</p><p><blockquote>“也有可能是Moderna疫苗中使用的mRNA本身导致了这种差异，与疫苗的剂量或两次注射的时间无关，”耶鲁大学医学传染病专家兼副教授Richard Martinello医学博士告诉Verywell，他没有参与这项研究。</blockquote></p><p> The Moderna vaccine contains more mRNA within the vaccine compared to the Pfizer dosage. And doses are given 28 days apart, compared to 21 days for the Pfizer vaccine.</p><p><blockquote>与辉瑞剂量相比，Moderna疫苗在疫苗中含有更多的mRNA。接种间隔28天，而辉瑞疫苗为21天。</blockquote></p><p> Still, further research is needed to understand why Moderna produced more antibodies. Experts still aren't sure if varying antibody levels translate to a difference in protection against COVID-19.</p><p><blockquote>尽管如此，还需要进一步的研究来了解为什么Moderna会产生更多的抗体。专家们仍然不确定不同的抗体水平是否会转化为对COVID-19保护的差异。</blockquote></p><p> <b>Antibody Tests Don’t Tell the Whole Story</b></p><p><blockquote><b>抗体测试并不能说明全部情况</b></blockquote></p><p> The study has notable limitations since it focused solely on healthcare workers and did not include data on cellular immunity.</p><p><blockquote>这项研究有明显的局限性，因为它只关注医护人员，不包括细胞免疫的数据。</blockquote></p><p> “Antibody levels have been found to provide a good measure of one’s protection against infection,” Martinello says. “However, it is known that cellular immunity plays a key role in the protection against and response to COVID. This is much more difficult to measure so it is not a routine test available from clinical laboratories. Therefore, while it is possible that the Moderna vaccine may be found to be more protective than the Pfizer vaccine, that remains to be seen.”</p><p><blockquote>“已经发现抗体水平可以很好地衡量一个人对感染的保护，”马蒂内洛说。“然而，众所周知，细胞免疫在预防和应对COVID方面发挥着关键作用。这更难测量，因此它不是临床实验室可用的常规测试。因此，虽然Moderna疫苗可能会被发现比辉瑞疫苗更具保护性，但这还有待观察。”</blockquote></p><p> A May study found that antibody levels can be predictive of protection from COVID-19 infection, but the researchers acknowledged that it's important to study T cell and B cell memory responses as well.</p><p><blockquote>5月份的一项研究发现，抗体水平可以预测对COVID-19感染的保护，但研究人员承认，研究T细胞和B细胞记忆反应也很重要。</blockquote></p><p> Although antibody levels are much simpler and cheaper to measure, and higher levels are likely to be more protective, they’re not a good measure of the degree and/or duration of protection an individual has against COVID-19,Stanley H. Weiss, MD, professor of medicine at the Rutgers New Jersey Medical School and professor of biostatistics at the Rutgers School of Public Health, tells Verywell.</p><p><blockquote>罗格斯大学新泽西医学院医学教授和罗格斯大学公共卫生学院生物统计学教授Stanley H.Weiss医学博士告诉Verywell，尽管抗体水平的测量更简单、更便宜，而且更高的水平可能更具保护性，但它们并不能很好地衡量个人对新冠肺炎的保护程度和/或持续时间。</blockquote></p><p> Earlier this year, the Food and Drug Administration (FDA) issued guidance saying that antibody tests should not be used to assess COVID-19 immunity after vaccination.3Researchers say that antibody tests are valuable public health tools that have very little use for individuals, and should not influence personal decision-making.</p><p><blockquote>今年早些时候，美国食品药品监督管理局（FDA）发布指南称，抗体测试不应用于评估接种疫苗后的新冠肺炎免疫力。3研究人员表示，抗体测试是有价值的公共卫生工具，对个人用处不大，不应影响个人决策。</blockquote></p><p> “There is ample data showing that some persons without any detectable antibodies have good protection due to cellular immunity,” Weiss says. “There is also ample data of breakthrough infection among persons who have anti-Covid antibodies.”</p><p><blockquote>“有大量数据表明，一些没有任何可检测抗体的人由于细胞免疫而具有良好的保护作用，”韦斯说。“也有大量数据表明具有抗新冠抗体的人出现突破性感染。”</blockquote></p><p> A March study found that cellular immunity remains robust six months after natural infection even though antibodies against the virus may fall below detectable levels. The findings show promise that COVID-19 vaccines elicit a similar response in the body.</p><p><blockquote>三月份的一项研究发现，尽管针对病毒的抗体可能低于可检测水平，但自然感染后六个月细胞免疫力仍然很强。这些发现表明，新冠肺炎疫苗有望在体内引发类似的反应。</blockquote></p><p> “In an individual person for clinical purposes, and especially outside of a carefully designed research study, I recommend against antibody testing,” Weiss says. “Neither a positive nor negative result gives you definitive information. My recommendation is for a decision to be based on general clinical criteria, not on an antibody test.”</p><p><blockquote>“出于临床目的，尤其是在精心设计的研究之外，我建议不要对个人进行抗体测试，”韦斯说。“阳性或阴性结果都不能给你明确的信息。我的建议是根据一般临床标准做出决定，而不是根据抗体测试。”</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118676828","content_text":"Moderna stock jumped 4% in morning trading as a recent study found that the Moderna COVID-19 vaccine produces higher antibody levels than the Pfizer-BioNTech vaccine.\n\n\nA recent study found that the Moderna COVID-19 vaccine produces higher antibody levels than the Pfizer-BioNTech vaccine.\nThis is possibly due to its higher mRNA content and a longer waiting period between doses.\nAntibody tests are not entirely predictive of the body’s immunity against COVID-19.\n\nA recent study found that the Moderna COVID-19 vaccine produced twice as many antibodies in recipients as the Pfizer-BioNTech vaccine.\nThe August study, published in JAMA, compared the antibody levels of 1647 healthcare workers before and six to 10 weeks after vaccination. The researchers observed significantly higher antibody levels among the recipients of the Moderna vaccine compared to the recipients of the Pfizer-BioNTech vaccine.\nAmong all the participants who had a previous COVID-19 infection, those who were vaccinated with the Moderna vaccine still carried more antibodies.\nHowever, more research is needed to understand whether the difference in antibody levels leads to different levels of protection against the virus. Experts stress that testing for antibodies isn't the only way of measuring protection.\nWhy Does Moderna Produce Higher Antibody Levels?\nAccording to the authors of the study, the Moderna COVID-19 vaccine contains more mRNA and requires a longer waiting period than Pfizer-BioNTech, which may have played a role.\n“It is also possible that the mRNA itself used in the Moderna vaccine may have led to this difference independent of the dose in the vaccine or the timing of the two shots,\"Richard Martinello, MD, Yale Medicine infectious diseases specialist and associate professor of medicine and pediatrics at the Yale School of Medicine, who was not involved in the study, tells Verywell.\nThe Moderna vaccine contains more mRNA within the vaccine compared to the Pfizer dosage. And doses are given 28 days apart, compared to 21 days for the Pfizer vaccine.\nStill, further research is needed to understand why Moderna produced more antibodies. Experts still aren't sure if varying antibody levels translate to a difference in protection against COVID-19.\nAntibody Tests Don’t Tell the Whole Story\nThe study has notable limitations since it focused solely on healthcare workers and did not include data on cellular immunity.\n“Antibody levels have been found to provide a good measure of one’s protection against infection,” Martinello says. “However, it is known that cellular immunity plays a key role in the protection against and response to COVID. This is much more difficult to measure so it is not a routine test available from clinical laboratories. Therefore, while it is possible that the Moderna vaccine may be found to be more protective than the Pfizer vaccine, that remains to be seen.”\nA May study found that antibody levels can be predictive of protection from COVID-19 infection, but the researchers acknowledged that it's important to study T cell and B cell memory responses as well.\nAlthough antibody levels are much simpler and cheaper to measure, and higher levels are likely to be more protective, they’re not a good measure of the degree and/or duration of protection an individual has against COVID-19,Stanley H. Weiss, MD, professor of medicine at the Rutgers New Jersey Medical School and professor of biostatistics at the Rutgers School of Public Health, tells Verywell.\nEarlier this year, the Food and Drug Administration (FDA) issued guidance saying that antibody tests should not be used to assess COVID-19 immunity after vaccination.3Researchers say that antibody tests are valuable public health tools that have very little use for individuals, and should not influence personal decision-making.\n“There is ample data showing that some persons without any detectable antibodies have good protection due to cellular immunity,” Weiss says. “There is also ample data of breakthrough infection among persons who have anti-Covid antibodies.”\nA March study found that cellular immunity remains robust six months after natural infection even though antibodies against the virus may fall below detectable levels. The findings show promise that COVID-19 vaccines elicit a similar response in the body.\n“In an individual person for clinical purposes, and especially outside of a carefully designed research study, I recommend against antibody testing,” Weiss says. “Neither a positive nor negative result gives you definitive information. My recommendation is for a decision to be based on general clinical criteria, not on an antibody test.”","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1715,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":888158977,"gmtCreate":1631461211999,"gmtModify":1631890895224,"author":{"id":"4089439192591850","authorId":"4089439192591850","name":"Winson96","avatar":"https://static.tigerbbs.com/ccaab866d210ccee630438cdf8ab4194","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089439192591850","idStr":"4089439192591850"},"themes":[],"htmlText":"Up up up, to the sky😀","listText":"Up up up, to the sky😀","text":"Up up up, to the sky😀","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/888158977","isVote":1,"tweetType":1,"viewCount":1591,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885181835,"gmtCreate":1631764947127,"gmtModify":1631890895188,"author":{"id":"4089439192591850","authorId":"4089439192591850","name":"Winson96","avatar":"https://static.tigerbbs.com/ccaab866d210ccee630438cdf8ab4194","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089439192591850","idStr":"4089439192591850"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/885181835","repostId":"1118309831","repostType":4,"repost":{"id":"1118309831","kind":"news","pubTimestamp":1631761632,"share":"https://www.laohu8.com/m/news/1118309831?lang=zh_CN&edition=full","pubTime":"2021-09-16 11:07","market":"us","language":"en","title":"Cathie Wood Sells Another $61.7M Tesla Shares, Marking 4th Day Of Trimming Stake In Elon Musk Company This Month<blockquote>Cathie Wood又出售了价值6170万美元的特斯拉股票，这是本月第四天减持Elon Musk公司股份</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1118309831","media":"Benzinga","summary":"Cathie Wood-led Ark Invest on Wednesday further trimmed some of its stake in Tesla Inc, booking prof","content":"<p><div> Cathie Wood-led Ark Invest on Wednesday further trimmed some of its stake in Tesla Inc, booking profits as the stock continued to show signs of recovery after months of dull performance this year. The...</p><p><blockquote><div>凯西·伍德(Cathie Wood)领导的方舟投资(Ark Invest)周三进一步减持了特斯拉公司的部分股份，由于该股在今年数月的低迷表现后继续显示出复苏迹象，因此录得利润。这...</div></blockquote></p><p>  <a href=\"https://www.benzinga.com/news/21/09/22964062/cathie-wood-sells-another-61-7m-tesla-shares-marking-4th-day-of-trimming-stake-in-elon-musk-company\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://www.benzinga.com/news/21/09/22964062/cathie-wood-sells-another-61-7m-tesla-shares-marking-4th-day-of-trimming-stake-in-elon-musk-company\">网页连接</a></blockquote></p><p></p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Sells Another $61.7M Tesla Shares, Marking 4th Day Of Trimming Stake In Elon Musk Company This Month<blockquote>Cathie Wood又出售了价值6170万美元的特斯拉股票，这是本月第四天减持Elon Musk公司股份</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Sells Another $61.7M Tesla Shares, Marking 4th Day Of Trimming Stake In Elon Musk Company This Month<blockquote>Cathie Wood又出售了价值6170万美元的特斯拉股票，这是本月第四天减持Elon Musk公司股份</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Benzinga</strong><span class=\"h-time small\">2021-09-16 11:07</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> Cathie Wood-led Ark Invest on Wednesday further trimmed some of its stake in Tesla Inc, booking profits as the stock continued to show signs of recovery after months of dull performance this year. The...</p><p><blockquote><div>凯西·伍德(Cathie Wood)领导的方舟投资(Ark Invest)周三进一步减持了特斯拉公司的部分股份，由于该股在今年数月的低迷表现后继续显示出复苏迹象，因此录得利润。这...</div></blockquote></p><p>  <a href=\"https://www.benzinga.com/news/21/09/22964062/cathie-wood-sells-another-61-7m-tesla-shares-marking-4th-day-of-trimming-stake-in-elon-musk-company\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://www.benzinga.com/news/21/09/22964062/cathie-wood-sells-another-61-7m-tesla-shares-marking-4th-day-of-trimming-stake-in-elon-musk-company\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.benzinga.com/news/21/09/22964062/cathie-wood-sells-another-61-7m-tesla-shares-marking-4th-day-of-trimming-stake-in-elon-musk-company\">Benzinga</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.benzinga.com/news/21/09/22964062/cathie-wood-sells-another-61-7m-tesla-shares-marking-4th-day-of-trimming-stake-in-elon-musk-company","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118309831","content_text":"Cathie Wood-led Ark Invest on Wednesday further trimmed some of its stake in Tesla Inc, booking profits as the stock continued to show signs of recovery after months of dull performance this year.\nThe popular asset management firm sold 81,609 shares — estimated to be worth $61.7 million — in the Elon Musk-led company on Wednesday, its fourth such trade in Tesla in September.\nWith the latest sales, Ark Invest has trimmed a total of 354,181 shares — estimated to be worth about $267.7 million — in the Palo Alto, California-based company so far this month.\nTesla shares, which have risen about 6% since the beginning of this month, closed 1.52% higher at $755.83 a share on Wednesday. On a YTD basis, Tesla shares have risen about 3.57%.\nArk Invest deployed the Ark Next Generation Internet ETF\nARKW+undefined%and the Ark Innovation ETFARKK+undefined%to sell shares in Tesla. Ark Invest also owns shares in Tesla via the Ark Autonomous Technology & Robotics ETF(BATS:ARKQ).\nThe popular New York-based investment management firm has a large exposure in Tesla, a stock it predicts will hit the$3,000 mark at the end of 2025.  Ark Invest has bought most of Tesla shares at far lower levels and Wood has said the firm isn't hesitant in booking profits on portfolio companies when they run up too high and then buy back at lower prices once they retreat.\nTesla ranks as the top-most-holding in each of the three ETFs and Ark held a total of 4.21 million shares — worth $3.13 billion — in the electric vehicle company, ahead of Wednesday’s trades. No other Ark ETF owns shares in Tesla.\nHere are some of the other key trades for Ark on Wednesday:\nBought 92,058 shares in Robinhood Markets Inc\nSold 2,398 shares in Alphabet Inc\nBought 538,680 shares in UiPath Inc\nSold 62,840 shares in Iridium Communications Inc","news_type":1,"symbols_score_info":{"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":2622,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885183363,"gmtCreate":1631764806652,"gmtModify":1631890895198,"author":{"id":"4089439192591850","authorId":"4089439192591850","name":"Winson96","avatar":"https://static.tigerbbs.com/ccaab866d210ccee630438cdf8ab4194","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089439192591850","idStr":"4089439192591850"},"themes":[],"htmlText":"[Grin]&nbsp;","listText":"[Grin]&nbsp;","text":"[Grin]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/885183363","repostId":"2167592712","repostType":4,"isVote":1,"tweetType":1,"viewCount":1434,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}